Yesterday’s Capital Markets Event provided a highly encouraging overview of the company’s development and commercialisation plans for its key products (the erectogenic condom CSD500, the MED2002 topical gel for erectile dysfunction, and the topical pain relief products TPR100/diclofenac and TIB200/ibuprofen). We continue to expect exciting newsflow ahead: first regulatory approval of CSD500 following a successful shelf life extension project and headline data from the clinical trial of MED2002 a ....
